BioNTech (NASDAQ:BNTX) Shares Gap Down to $92.72

BioNTech SE (NASDAQ:BNTX) shares gapped down prior to trading on Monday . The stock had previously closed at $92.72, but opened at $90.09. BioNTech shares last traded at $92.49, with a volume of 481,363 shares trading hands.

Analysts Set New Price Targets

Several research firms recently commented on BNTX. HC Wainwright reissued a “buy” rating and set a $107.00 price target on shares of BioNTech in a research report on Wednesday, April 17th. The Goldman Sachs Group lowered their price objective on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. UBS Group cut their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. Canaccord Genuity Group restated a “buy” rating and set a $171.00 price target on shares of BioNTech in a research report on Thursday, March 21st. Finally, JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research report on Friday, March 22nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, BioNTech presently has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Trading Up 0.7 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The business has a 50 day simple moving average of $90.54 and a 200 day simple moving average of $95.99. The company has a market cap of $22.19 billion, a price-to-earnings ratio of 22.39 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. As a group, equities analysts forecast that BioNTech SE will post -1.74 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. increased its position in shares of BioNTech by 3.9% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock worth $432,000 after acquiring an additional 148 shares in the last quarter. Raymond James & Associates raised its stake in shares of BioNTech by 5.6% in the 3rd quarter. Raymond James & Associates now owns 5,579 shares of the company’s stock valued at $606,000 after purchasing an additional 298 shares during the period. Mackenzie Financial Corp lifted its holdings in shares of BioNTech by 86.5% in the third quarter. Mackenzie Financial Corp now owns 5,131 shares of the company’s stock valued at $558,000 after purchasing an additional 2,380 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of BioNTech by 9.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 81,103 shares of the company’s stock worth $8,811,000 after buying an additional 6,682 shares during the period. Finally, Flossbach Von Storch AG raised its position in BioNTech by 2.1% in the 3rd quarter. Flossbach Von Storch AG now owns 3,513,215 shares of the company’s stock valued at $381,676,000 after buying an additional 71,468 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.